Document is current
Any future updates will be listed below
-
Authors
Kato, Shingo https://orcid.org/0000-0002-9030-0474
Teixeira, Bruno Casaes https://orcid.org/0000-0003-2366-0960
Laurent, Thomas https://orcid.org/0000-0002-7053-8469
Yamada, Yoshiyuki https://orcid.org/0000-0001-5040-8723
Dave, Kiran
Shah, Shweta
Kim, Hyunchung https://orcid.org/0000-0002-2149-2345
- License Information
-
More Information
Article History
Received: 2 October 2024
Accepted: 13 December 2024
First Online: 24 January 2025
Declarations
:
: Shingo Kato received honoraria from AbbVie, Janssen Pharmaceutical K.K., Kissei, Mitsubishi Tanabe, and Takeda. Bruno Casaes Teixeira, Thomas Laurent, Yoshiyuki Yamada, Kiran Dave, Shweta Shah, and Hyunchung Kim are employees and/or shareholders of Bristol Myers Squibb.
: This real-world, retrospective, observational study used anonymized patient data from June 2018 to December 2022, obtained from Medical Data Vision, a hospital-based claims database (Medical Data Vision, Tokyo, Japan) that covers approximately 42 million patients across 474 acute care hospitals in Japan. As all data were anonymized, requirements for ethics approval and informed consent under the Ethical Guidelines for Epidemiological Research in Japan do not apply to this study. Permission was obtained to access and use data by Medical Data Vision.
